Physician

Yong H Tsai, M.D.

According to 2025 Medicare claims, Yong Tsai, M.D. (NPI: 1659363505) practices rheumatology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is ARTHRITIS AUTOIMMUNE AND ALLERGY (NPI: 1417148032; TIN: 331155955) and primary practice location at 32117-5536.

Tsai's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 864 traditional Medicare patients, billed 218,523 HCPCS/CPT codes, and received $1,920,195 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 10,203 prescription claims across 1,595 beneficiaries totaling $7,655,250 in drug costs, led by Enbrel Mini (Etanercept). 2022 DME data shows 18 claims. Open Payments data shows 70 records totaling $72,576. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,148,461 to $1,920,195. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,059,119 to $7,655,250. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	912	119,811	$1,148,461
2016	856	101,466	$1,045,538
2017	866	108,166	$1,304,079
2018	946	121,992	$1,532,215
2019	930	129,265	$1,709,823
2020	796	152,013	$1,868,983
2021	803	177,145	$2,160,003
2022	829	203,128	$2,089,043
2023	831	211,184	$2,170,041
2024	864	218,523	$1,920,195

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,305	13,034	$2,059,119
2016	1,372	12,785	$2,313,132
2017	1,370	11,606	$2,858,410
2018	1,385	10,878	$3,452,859
2019	1,295	10,116	$4,269,382
2020	1,234	9,249	$4,321,545
2021	1,274	8,280	$4,287,125
2022	1,288	7,778	$5,229,380
2023	1,464	9,155	$7,703,795
2024	1,595	10,203	$7,655,250

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	57	$88,512
2017	N/R	61	$66,922
2018	N/R	23	$1,159
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	15	$1,145
2022	N/R	18	$1,270
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	232	232	$126
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	564	1,083	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	232	311	$64
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	135	911	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	442	557	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Mini	Etanercept	95	3,054	$806,908
Enbrel Sureclick	Etanercept	97	2,716	$737,436
Humira(Cf)	Adalimumab	89	2,660	$656,098
Enbrel	Etanercept	73	2,212	$585,959
Skyrizi Pen	Risankizumab-Rzaa	27	2,224	$560,225

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$841	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	34	$71,735	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Yong H. Tsai, M.D.?

Tedicare shows public-source Medicare data for Yong H. Tsai, M.D. (NPI 1659363505), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Yong H. Tsai, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Yong H. Tsai, M.D.?

Yong H. Tsai, M.D. is linked to ARTHRITIS AUTOIMMUNE AND ALLERGY (billing NPI 1417148032) in the available physician profile data.

Does Yong H. Tsai, M.D. have Open Payments data?

Yong H. Tsai, M.D. has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.